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ABSTRACT
Realizing the full therapeutic potential of mesenchymal stromal/stem cells (MSCs) awaits
improved understanding of mechanisms controlling their fate. Using MSCs cultured as spheroids
to recapitulate a three-dimensional cellular environment, we show that perturbing the mesen-
chymal regulators, platelet-derived growth factor (PDGF) receptors or fibronectin, reverts MSCs
toward mesodermal progenitors with endothelial potential that can potently induce neovascula-
rization in vivo. MSCs within untreated spheroids retain their mesenchymal spindle shape with
abundant smooth muscle a-actin filaments and fibronectin-rich matrix. Inhibiting PDGF recep-
tors or depleting fibronectin induces rounding and depletes smooth muscle a-actin expression;
these cells have characteristics of mesenchymoangioblasts, with enhanced expression of mesen-
doderm and endoderm transcription factors, prominent upregulation of E-cadherin, and Janus
kinase signaling-dependent expression of Oct4A and Nanog. PDGF receptor-inhibited spheroids
also upregulate endothelial markers platelet endothelial cell adhesion molecule 1 and vascular
endothelial-cadherin and secrete many angiogenic factors, and in vivo they potently stimulate
neovascularization, and their MSCs integrate within functional blood vessels that are perfused
by the circulation. Thus, MSC potency and vascular induction are regulated by perturbing mes-
enchymal fate. STEM CELLS 2014;32:694–705
INTRODUCTION
Fulfilling the potential of mesenchymal stromal
(stem) cells (MSCs) in regenerative medicine
requires an improved understanding of the
mechanisms that control their fate. It is well
known that, in adherent cultures, MSCs adopt
a myofibroblast-like contractile phenotype and
can differentiate along mesenchymal lineages
in response to defined supplements [1, 2]. Less
is known about MSCs in vivo and even the lin-
eage specification of their embryonic precur-
sors is ill-defined [3, 4]. MSCs occupy
perivascular niches throughout the body [5]
and in the bone marrow can undergo osteo-
genic differentiation and support hematopoie-
sis [6, 7]. Although MSCs can express
endothelial markers in vitro in response to
growth factors [8], or to cell density-dependent
Notch signals [9], their ability to form func-
tional vascular endothelium and contribute to
new blood vessel formation in vivo remains
uncertain. We report that MSC fate is changed
by perturbing mesenchymal regulators, which
in turn stimulates neovascularization and their
integration into functional blood vessels.
MSCs are derived predominantly from the
mesodermal lineage, but also from endoderm
by epithelial-mesenchymal transition and from
ectodermal neural crest [10–12]. During devel-
opment, the mesoderm forms distinct mesen-
chymal and hemato-endothelial lineages. Using
embryonic stem cells directed toward mesen-
doderm, one group identified a common
mesoderm-derived precursor for MSCs and
endothelial cells, which they termed a mesen-
chymoangioblast [3, 4]. Others described a
bone marrow mesodermal progenitor cell pop-
ulation with dual mesenchymal and endothe-
lial differentiation potential [13]. These data
point to a mesodermal cell stage with poten-
tial to form mesenchyme or endothelium.
Platelet-derived growth factor (PDGF) recep-
tors (PDGFR) are markers and critical regulators of
mesenchyme [14–16]. Knockout mice showed
that loss of PDGFRa or PDGF-A disrupts mesen-
chymal tissue formation, whereas loss of PDGFRb
disrupts pericytes and smooth muscle [17, 18].
Knockout of PDGFRa caused death of 50% of
embryos before E10 and the rest shortly after
birth [19], while in chick, signaling through
PDGFRa was required for mesodermal cell migra-
tion [20].We have shown that PDGFR signaling in
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TISSUE-SPECIFIC STEM CELLS
MSCs regulatesmigration, proliferation, and cytoskeletal organiza-
tion, through RhoA/Rho kinase (ROK) signaling [21] and by cross-
talk with fibronectin (FN)-activated integrin a5b1 [22] and
neuropilin-1 [23]. We showed that FN/a5b1 activates PDGFRb in
the absence of PDGF growth factors, and is also required to poten-
tiate PDGF-BB-mediated PDGFRb activation [22]. FN, a chordate
innovation, is an extracellular adhesive glycoprotein [24], which
controls the deposition of fibrillar matrices by mesenchymal cells
[25], and thus tissue formation. FN-null mice are early embryonic
lethal due to multiple cardiovascular defects [26]. PDGFRb signal-
ing enhances FN expression [27], and together they are potent
drivers of mesenchyme.
We have tested the hypothesis that disrupting mesenchy-
mal regulators can alter the fate of human bone marrow-
derived MSCs. Cell cytoskeleton was modified by inhibiting
PDGFRs or by depleting FN, within three-dimensional (3D) sphe-
roids. Resulting MSCs were rounded rather than spindle-
shaped, with depleted smooth muscle a-actin (SMA) filaments
and greatly reduced migratory capacity. They were mesenchy-
moangioblast-like with enhanced transcription factors such as
EOMES, Foxh1, and Mixl1. These cells also exhibited marked
upregulation of E-cadherin, Oct4A, and Nanog as well as endo-
thelial markers platelet endothelial cell adhesion molecule 1
(PECAM-1) and vascular endothelial (VE)-cadherin and angio-
genic growth factors. They had endothelial-like organization,
and markedly enhanced neovascularization and integration into
new functional blood vessels that were perfused by the circula-
tion in vivo. Thus, perturbation of mesenchymal regulators
modulates MSC fate and angiogenic potential in vivo. This dis-
covery offers opportunities for therapeutic revascularization.
MATERIALS AND METHODS
Cell Culture and Spheroid Formation
Human bone marrow-derived MSCs from a 21-year-old female,
and 21- and 33-year-old males (Lonza, Allendale, NJ, http://
www.lonza.com), were subcultured on 0.1% gelatin, maintained
in MesenPRO RS growth medium (Life Technologies, Grand
Island, NY, http://www.lifetechnologies.com), and used at pas-
sage 5. Spheroids were formed by seeding 60,000 MSCs in
growth medium6 0.1 mM PDGFR inhibitor-IV (EMD Millipore,
Billerica, MA, http://www.emdmillipore.com) [28], into individ-
ual wells of a low cell binding 96-well plate (Nunc 145399;
Thermo Scientific, Waltham, MA, http://www.thermofisher.
com) and cultured at 37C for 5 days. Other small molecular
inhibitors; EGFR (PD168393), FGFR (341608), VEGFR
(ZM323881), Rho-kinase (H-1152), Rac1 (553508), MEK
(PD98059), PI3K (LY294002), and JAK (Inhibitor I), were all
obtained from EMD Millipore, Billerica, MA, http://www.
emdmillipore.com and previously described [28].
Quantitative RT-PCR Analysis
For RNA isolation; 12 identically cultured spheroids were
pooled together for analysis. RNA was isolated using Trizol
reagent (Life Technologies, Grand Island, NY, http://www.life-
technologies.com) followed by digestion with RNase-free
DNase (Promega, Madison, WI, http://www.promega.com).
First strand cDNA synthesis was performed using AMV reverse
transcriptase (Roche, Basel, Switzerland, http://www.roche.-
com), and real-time quantitative PCR using GoTaq qPCR kit
(Qiagen, Valencia, CA, http://www.qiagen.com). Gene expres-
sion was determined relative to GAPDH using the DCt
method. All primer sequences are provided in Supporting
Information Table S1.
siRNA Knockdown
MSCs were transfected with 10 nM small interfering RNAs (siR-
NAs) using Lipofectamine RNAi MAX reagent (Life Technologies,
Grand Island, NY, http://www.lifetechnologies.com), then cul-
tured for 24 hours in the presence of the reagent and siRNA.
Transfected MSCs were then trypsinized and used to form sphe-
roids in the presence of fresh Lipofectamine reagent and siRNA
which remained in the culture at 37C for 5 days. Validated siR-
NAs were used to knockdown FN (1027417) (Qiagen, Valencia,
CA, http://www.qiagen.com); scrambled siRNA (Qiagen, Valencia,
CA, http://www.qiagen.com) was used as a control.
Immunoblotting
For protein isolation; 12 identically cultured spheroids were
pooled together for analysis. Protein lysate isolation, immunoblot-
ting, and quantification were performed as previously described
[21]. Details of the antibodies used are given in Supporting Infor-
mation Table S2.
Matrigel In Vitro Network and Implant Analysis
For network formation, spheroids were dissociated into single
cells by incubation with 0.001% (wt/vol) collagenase type IV
(Sigma Aldrich, St. Louis, MO, http://www.sigmaaldrich.com) in
phosphate buffered saline for 1 hour at 37C, followed by Try-
pLE Select (Life Technologies, Grand Island, NY, http://www.life-
technologies.com) digestion for 10 minutes. MSCs were seeded
onto growth factor reduced Matrigel (BD Biosciences, San Jose,
CA, http://www.bdbiosciences.com) and incubated at 37C. For
implants, spheroids were covered with Matrigel and incubated
at 37C.
Matrigel Plug In Vivo Angiogenesis Assay
Spheroids suspended in 200 ml growth medium and 500 ml of
growth factor reduced Matrigel were injected subcutaneously
into the flanks of 6–8-week-old C57BL/6 mice. Five mice were
each injected with 10 control spheroids and five with 10
PDGFR-IV spheroids. Two weeks after injection, mice were
sacrificed, plugs removed, and immediately fixed in 4% (wt/
vol) paraformaldehyde for 24 hours at 4C, then incubated in
30% (wt/vol) sucrose solution for 24 hours at 4C. Plugs were
then embedded in OCT and 10 mm sections obtained for
immunofluorescence analysis which was performed as previ-
ously described [28].
To study whether new blood vessels were functional and
integrated with the circulation, 200 ml of 50 mg/ml FITC-
dextran 2,000 kDa (Sigma Aldrich, St. Louis, MO, http://
www.sigmaaldrich.com) was injected into the tail vein of mice,
and allowed to perfuse for 10 minutes before the mice were
sacrificed, and the plugs excised and processed, as above.
Whole Mount Immunofluorescence Analysis and
Microscopy
Spheroids were prepared for confocal microscopy as described
[29]. Details of the antibodies used are given in Supporting
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Information Table S2. Images were collected on a Nikon C1 confo-
cal using a TE2000 PSF inverted microscope, using 360 /NA 1.40
Plan Apo or 320/NA 0.50 Plan Fluor objectives and 33 confocal
zoom. Different sample images detecting the same antibodies
were acquired under constant acquisition settings. Images were
processed using Nikon EZ-C1 FreeViewer v3.3 software. Bright-
field images were collected on an Olympus BX51 widefield micro-
scope, using a 310/NA 0.3 UPlan F1 objective. Images were cap-
tured with a CoolSNAP camera system and processed using
MetaMorph imaging v5.0 software.
Statistical Analysis
Results are expressed as the mean6 SD. Statistical differences
between sets of data were determined using a paired Stu-
dent’s t test, with p< .05 considered significant.
RESULTS
PDGFRs regulate the formation of mesenchymal cells from
mesoderm [14, 16]. These cells in turn make tissues by depos-
iting and embedding themselves within a FN-rich extracellular
matrix [24, 25]. FN/a5b1 is functionally linked with PDGFRb,
both by activating PDGFRb in the absence of PDGF growth
factors and by potentiating PDGF-BB-induced PDGFRb signal-
ing [22]. Here, we used 3D spheroid cultures to test the
hypothesis that cytoskeletal changes induced by inhibiting
these functionally integrated mesenchymal regulators, PDGFR
signaling and FN, revert MSCs toward a mesodermal progeni-
tor with endothelial potential.
PDGFR Signaling Modulates MSC Spheroid Assembly
and Organization
PDGFR signaling regulates the expression of contractile SMA
filaments [14–16], which are not only a characteristic func-
tional feature of vascular smooth muscle cells [30] but also
abundantly expressed by MSCs [21], and are widely used as a
distinctive mesenchyme marker. Using live cell imaging, we
monitored the assembly of MSCs into control and PDGFR
inhibitor-IV spheroids during the first 20 hours of formation
(Supporting Information Video S1). While control MSC suspen-
sions rapidly aggregated to form a spheroid, their assembly in
the presence of PDGFR inhibitor-IV was markedly slower. After
6 hours of seeding, control MSCs formed a spheroid-like
structure which contains a distinct outer ring of cells (Fig.
1A(i)); this feature was not detected during the assembly of
PDGFR inhibitor-IV spheroids. After 20 hours of seeding, con-
trol MSCs formed a spherical structure (Fig. 1A(ii)), whereas
PDGFR inhibitor-IV spheroids had a larger diameter but more
flattened structure. These distinctive organizational features
were maintained throughout a 5-day culture period (Fig.
1A(iii)); MSCs within control 3D spheroids retained their char-
acteristic spindle-shaped morphology and expressed wide-
spread abundant extended SMA filaments and FN (Fig. 1B(i)).
However, MSCs within PDGFR inhibitor-IV spheroids were
more rounded, and SMA and FN abundance were markedly
reduced (Fig. 1B(i)). Within the core of the spheroids, MSCs
appeared viable and expressed abundant SMA filaments (Fig.
1B(ii)), which were diminished by PDGFR inhibitor-IV. Com-
pared to control spheroids at day 5, PDGFR inhibitor-IV sphe-
roids expressed 2.96 0.3-fold lower SMA protein (Fig. 1C).
PDGFRb is known to regulate FN expression [27]. Having
shown that PDGFR inhibitor-IV spheroids contained markedly
reduced SMA and FN, we used siRNA knockdown to investi-
gate how FN influences the fate of MSCs within 3D sphe-
roids. Compared to spheroids formed from scrambled siRNA
knockdown MSCs, spheroids assembled by FN knockdown
MSCs displayed a 79%6 9% reduction in FN protein (Fig.
1D) expression, respectively, by day 5 of culture. Like the
PDGFR inhibitor-IV treated spheroids (Fig. 1A), these FN
knockdown spheroids had larger diameters than control
spheroids (Fig. 1E). The FN knockdown MSCs also appeared
more rounded and in closer contact than control cells and,
compared to scrambled siRNA knockdown spheroids, they
expressed markedly reduced SMA filaments (Fig. 1B(iii)) and
had a 70%6 8% decrease in SMA protein expression (Fig.
1F). FN knockdown spheroids also displayed significantly
diminished PDGFRb phosphorylation (Y751 80%6 7% and
Y1021 85%6 8% reduction, respectively) (Fig. 1G, 1H). These
data show that PDGFRs, and FN which activates PDGFRs,
both regulate SMA contractile filaments and coordinate MSC
spheroid organization and contractility.
PDGFR Inhibition and FN Depletion Increase Oct4A
and Nanog Expression
Having shown that PDGFR inhibition and FN knockdown
altered MSC organization within 3D spheroids, we determined
their effects on expression of the pluripotency markers Oct4A
and Nanog. Compared to untreated adherent MSCs, control
spheroids increased Oct4A (5.56 0.6-fold) and Nanog
(6.46 0.5-fold) transcript levels, and PDGFR inhibitor-IV sphe-
roids further increased Oct4A (10.46 0.8-fold) and Nanog
(11.06 0.7-fold) (Fig. 2A). To compare these transcript levels
with those expressed by pluripotent human embryonic stem
cells (ESCs), we examined levels of Oct4A and Nanog
expressed by a human ESC line Hues1 (Fig. 2B). Compared to
control spheroids, PDGFR inhibitor-IV spheroids increased
Oct4A (2.16 0.2-fold) and Nanog (2.26 0.2-fold), while ESCs
demonstrated a greater level of Oct4A (5.36 0.4-fold) and
Nanog (4.66 0.4-fold). Oct4A and Nanog transcript expression
increased throughout the 5-day culture in both control and
PDGFR inhibitor-IV-treated spheroids, with the PDGFR
inhibitor-IV spheroids producing the greater increase (Fig. 2C).
Immunofluorescence analysis revealed no Oct4A and a
low abundance of Nanog within day 5 control spheroids
(Fig. 2D). In contrast, Nanog and Oct4A were initially
detected at day 3 and day 1, respectively, in PDGFR
inhibitor-IV spheroids (Supporting Information Fig. S1), and
both factors increased in abundance up to day 5 (Fig. 2D).
Both Nanog and Oct4A expression were dependent on
Janus kinase (JAK) signaling (Supporting Information Fig.
S2A, S2B), while nuclear STAT3 (Y705) and STAT1 (Y701)
increased markedly within PDGFR inhibitor-IV spheroids
(Supporting Information Fig. S2C). Compared to control
spheroids at day 5, PDGFR inhibitor-IV spheroids expressed
significantly higher levels of both Oct4A (3.36 0.3-fold) (Fig.
2F) and Nanog (3.06 0.2-fold) protein (Fig. 2G), which were
JAK signaling-dependent (Supporting Information Fig. S2D).
Immunofluorescence analysis revealed that, while there was
no detectable Oct4A, and low Nanog expression within day 5
scrambled knockdown spheroids, FN knockdown spheroids mark-
edly increased Nanog and Oct4A expression (Fig. 2E). Immunoblot
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analysis also confirmed an increase in Oct4A (2.16 0.2-fold) (Fig.
2H) and Nanog (2.56 0.3-fold) (Fig. 2I), although these levels
were lower than in the PDGFR inhibitor-IV spheroids.
Thus, in comparison to adherent MSC cultures, spindle-
shaped MSCs within 3D control spheroids increased the expres-
sion of Oct4A and Nanog transcripts, although only low levels of
protein were detected. However, inhibition of PDGFR signaling or
FN knockdown within spheroids, which induced more rounded
MSCs, prominently upregulated Oct4A and Nanog protein levels.
MSC Spheroids Display a Mesendoderm Expression
Profile
Having established that MSCs cultured as 3D spheroids mark-
edly upregulate the expression of the pluripotency transcrip-
tion factors Nanog and Oct4A, we investigated expression
levels of mesendoderm and endoderm transcription factors
expressed by spheroids at day 5 (Fig. 3). Bipotent mesendo-
derm cells are precursors for both endoderm and mesoderm
during ESC differentiation [31]. Mesendoderm has been char-
acterized as goosecoid (Gsc)1 E-cadherin (CDH1)1 PDGFRa1
which can give rise to Gsc1 CDH11 PDGFRa2 endoderm and
Gsc1 CDH12 PDGFRa1 mesoderm progenitors [31]. Compared
to untreated adherent MSCs, control spheroids expressed
increased transcripts of mesendoderm transcription factors;
Nodal, Mixl, EOMES, Foxh1, and Gsc (Fig. 3A), but PDGFR
inhibitor-IV spheroids expressed higher levels of Mixl, EOMES,
and Foxh1 (Fig. 3A). Control spheroids also expressed
increased levels of the endoderm transcription factors; Foxa1,
Figure 1. PDGFR and FN inhibition changed mesenchymal stromal/stem cell (MSC) spheroid shape and SMA expression. (A): Bright-field
images of control and PDGFR inhibitor-IV treated MSCs during spheroid assembly, showing cells (i) 6 hours, (ii) 20 hours, and (iii) 5 days fol-
lowing seeding. Scale bars5 400 mm (i, ii) and 200 mm (iii). (B): Whole mount immunofluorescence analysis of (i, ii) control spheroids (con)
and PDGFR inhibitor-IV spheroids (IV), (iii) scrambled control siRNA spheroids (Scr #) and FN knockdown spheroids (FN #) cultured for 5
days, showing FN (red) and SMA (green) expression, with DAPI-stained nuclei (blue). Scale bars5 50 mm. (C): Immunoblot analysis of SMA
expression within control (Con) and PDGFR inhibitor-IV (IV) spheroids after 5 days culture, with b-actin as a loading control. Histogram
shows SMA expression relative to b-actin and normalized to control spheroid level. *, p< .001 compared with day 5 control spheroids, using
paired t test n 5 3 separate experiments, error bars represent SD. (D): Immunoblot analysis of FN expression within control scrambled
siRNA spheroids (Scr #) and FN knockdown spheroids (FN #) cultured for 5 days, with b-actin as a loading control. RNA expression is relative
to GAPDH and normalized to the level of scrambled control spheroids at day 5. Histogram shows protein expression relative to b-actin and
normalized to control siRNA spheroid level. *, p< .001 compared with control siRNA spheroids, using paired t test n 5 3 separate experi-
ments, error bars represent SD. (E): Bright-field images of spheroids assembled using MSCs treated with scrambled (Scr) or FN small interfer-
ing RNAs (siRNA) and cultured for 5 days. Scale bars5 200 mm. (F–H): Immunoblot analysis of SMA, PDGFRb Y751, and Y1021
phosphorylation levels, within scrambled control siRNA spheroids (Scr #) and FN knockdown spheroids (FN #) after 5 days culture, with b-
actin or PDGFRb as a loading control. Histograms show SMA expression relative to b-actin and PDGFRb Y751 and Y1021 relative to PDGFRb,
normalized to scrambled control siRNA spheroid level. *, p< .001 compared with control spheroids, using paired t test n 5 3 separate
experiments, error bars represent SD. Abbreviations: FN, fibronectin; PDGFR, platelet-derived growth factor receptor.
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Foxa2, a-fetoprotein (AFP), and Sox17 (Fig. 3B), which were
further increased in PDGFR inhibitor-IV spheroids (Fig. 3B).
We therefore examined the expression of the definitive
endoderm marker CDH1 [32], which is essential for maintain-
ing ESC pluripotency [33] and is implicated in iPS cell genera-
tion [34]. Compared to untreated adherent MSCs, control
spheroids expressed increased CDH1 (2.86 0.4-fold) tran-
script; however, levels of mesoderm markers CDH2, SMA, and
vimentin remained similar (Fig. 3C). In contrast, PDGFR
inhibitor-IV spheroids expressed significantly higher CDH1
(4.56 0.2-fold), whereas levels of CDH2, SMA, and vimentin
were markedly decreased (Fig. 3C). Compared to control sphe-
roids, PDGFR inhibitor-IV spheroids showed an increase of
1.86 0.1-fold in CDH1 transcript, while human ESCs demon-
strated a higher level (4.16 0.3-fold) (Fig. 3D). Immunofluo-
rescence analysis revealed no detectable CDH1 protein within
control spheroids (Fig. 3E), but CDH1 protein was readily
detected and characteristically localized at cell-cell boundaries
within PDGFR inhibitor-IV spheroids (Fig. 3E).
To investigate further the increased expression of pluripo-
tency and endoderm proteins within PDGFR inhibitor-IV sphe-
roids, a stem cell proteome array was used to detect relative
expression levels simultaneously (Supporting Information Fig.
S3A). Compared to control spheroids, PDGFR inhibitor-IV sphe-
roids showed a distinct increase in the pluripotent markers;
Oct4, Nanog, and Sox2, and endoderm markers; Sox17, AFP,
Figure 2. Platelet-derived growth factor receptor (PDGFR) and fibronectin (FN)-inhibited spheroids upregulate Oct4A and Nanog. (A):
Quantitative RT-PCR analysis of Oct4A and Nanog expression within high-density adherent mesenchymal stromal/stem cells (MSCs) (Adh
Con), high-density adherent MSCs exposed to PDGFR inhibitor-IV (Adh IV), control spheroids (Sph Con), and PDGFR inhibitor-IV spheroids
(Sph IV), cultured for 5 days. Data are relative to GAPDH and normalized to adherent control levels. *, p< .001 compared with adherent
controls, #, p< .001 compared with control spheroids, using paired t test n 5 3 separate experiments, error bars represent SD. (B):
Quantitative RT-PCR analysis of Oct4A and Nanog expression within control spheroids (Sph Con) and PDGFR inhibitor-IV spheroids (Sph
IV), cultured for 5 days, and human embryonic stem cell line Hues1. Data are relative to GAPDH and normalized to control spheroid lev-
els. *, p< .001 compared with control spheroids, using paired t test n 5 2 separate experiments, error bars represent SD. (C): Quantita-
tive RT-PCR analysis of Oct4A and Nanog expression within control spheroids (Con) and PDGFR inhibitor-IV spheroids (IV), cultured for
cultured for 1, 2, 3, and 5 days. Data are relative to GAPDH and normalized to the level of control spheroids at day 1. *, p< .001 com-
pared with day 1 control spheroids, using paired t test n 5 3 separate experiments, error bars represent SD. (D, E): Whole mount
immunofluorescence analysis of (D) control spheroids (Con) and PDGFR inhibitor-IV spheroids (IV), (E) scrambled control siRNA spheroids
(Scr #), and FN knockdown spheroids (FN #) cultured for 5 days, showing Nanog (red) and Oct4A (green) expression, with DAPI-stained
nuclei (blue). Scale bars5 50 mm. (F–I): Immunoblot analysis of Oct4A and Nanog expression within (F, G) control (Con) and PDGFR
inhibitor-IV (IV) spheroids and (H, I) scrambled control siRNA spheroids (Scr #) and FN knockdown spheroids (FN #) after 5 days culture,
with b-actin as a loading control. Histograms show Oct4A and Nanog expression relative to b-actin and normalized to control spheroid
or scrambled control siRNA control spheroid levels. *, p< .001 compared with control spheroids, using paired t test n 5 3 separate
experiments, error bars represent SD.
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Foxa2, and CDH1. These data verify that PDGFR inhibitor-IV
spheroids express mesendoderm and endoderm markers includ-
ing CDH1, indicating features of a mesendoderm progenitor.
Proteome array analysis demonstrated that, compared to
scrambled siRNA knockdown spheroids, FN knockdown spheroids
also upregulated Oct4, Nanog, and Sox2 as well as endoderm
markers; Sox17, AFP, Foxa2, and CDH1 (Supporting Information
Fig. S3B). Thus, FN knockdown also resulted in features of a mes-
endoderm progenitor, although the relative levels of these
markers were lower than those induced by PDGFR inhibition
(Supporting Information Fig. S3A). These data indicate that inhibi-
tion of PDGFR signaling, or FN depletion, within spheroids
reverts MSCs toward a more multipotent state.
MSC Spheroids Exhibit Endothelial Characteristics
Using mesoderm progenitor cells derived from ESCs, activation
of PDGFRb signaling can induce differentiation to vascular
smooth muscle cells, which express abundant SMA, whereas
stimulation with VEGF-A can induce differentiation toward
endothelial cells [35]. In addition, adherent MSCs cultured in
two-dimensional (2D) at high density acquire a more rounded
cobblestone-like morphology, and can undergo differentiation
toward an endothelial lineage [9]. We therefore explored the
possibility that MSCs within PDGFR inhibitor-IV spheroids,
which lack PDGFR signaling, have depleted SMA and are at high
density, may exhibit an endothelial rather than mesenchymal
disposition. Accordingly, the expression of two characteristic
endothelial markers, PECAM-1 and VE-cadherin, was deter-
mined in PDGFR inhibitor-IV spheroids.
Compared to untreated adherent MSCs, control spheroids
expressed significantly increased PECAM-1 (6.76 0.7-fold) and VE-
cadherin (6.46 0.6-fold) transcript levels (Fig. 4A). However, com-
pared to control spheroids, PDGFR inhibitor-IV spheroids
expressed an even higher level of PECAM-1 (2.16 0.23-fold) and
VE-cadherin (1.66 0.17-fold) (Fig. 4A). Control spheroids increased
the level of both PECAM-1 and VE-cadherin transcripts up to day
5, while PDGFR inhibitor-IV spheroids produced a greater increase
(Fig. 4B). Immunofluorescence analysis revealed that control sphe-
roids, which contained spindle-shaped MSCs, expressed both
PECAM-1 and VE-cadherin protein, which increased up to day 5
(Fig. 4C and Supporting Information Fig. S4A). Similarly, PDGFR
inhibitor-IV spheroids, which contained more rounded MSCs, dis-
played prominent PECAM-1 and VE-cadherin expression, but in
this case the protein appeared localized around individual cells
(Fig. 4D and Supporting Information Fig. S4B). Compared to con-
trol spheroids at day 5, PDGFR inhibitor-IV spheroids significantly
expressed a higher level of PECAM-1 protein (2.46 0.2-fold) (Fig.
4E), which was JAK signaling dependent (Supporting Information
Fig. S2D–S2F). Compared to PDGFR inhibitor-IV spheroids, human
umbilical vein endothelial cells (HUVECs) expressed a greater level
of PECAM-1 (2.76 0.4-fold).
FN knockdown spheroids, which caused similar effects on
cell shape and phenotype (Fig. 1), increased PECAM-1 protein
(1.96 0.17-fold) (Fig. 4F). The effects of EGFR, FGFR, VEGFR,
ROK, Rac, MEK, or PI3K signaling inhibitors on PECAM-1 and
VE-cadherin transcripts were also examined, but only ROK or
Rac inhibition markedly increased PECAM-1 expression (Fig.
4G). Rac or ROK-inhibited spheroids were shown to increase
Figure 3. Platelet-derived growth factor receptor (PDGFR)-inhibited spheroids express E-cadherin. (A–C): Quantitative RT-PCR analysis
of (A) Nodal, Mixl1, EOMES, Foxh1, and Goosecoid (Gsc) (B) Foxa1, Foxa2, AFP, and Sox17, (C) E-cadherin (CDH1), N-cadherin (CDH2),
SMA, and vimentin (VIM), within high-density adherent mesenchymal stromal/stem cells (MSCs) (Adh con), high-density adherent MSCs
exposed to PDGFR inhibitor-IV (Adh IV), control spheroids (Sph con), and PDGFR inhibitor-IV spheroids (Sph IV), cultured for 5 days.
Data are relative to GAPDH and normalized to adherent control levels. *, p< .001 compared with adherent controls, #, p< .005 com-
pared with control spheroids, using paired t test n 5 3 separate experiments, error bars represent SD. (D): Quantitative RT-PCR analysis
of CDH1 within control spheroids (Sph Con) and PDGFR inhibitor-IV spheroids (Sph IV), cultured for 5 days, and human ESC line Hues1.
Data are relative to GAPDH and normalized to control spheroid levels. *, p< .001 compared with spheroid controls, using paired t test
n 5 2 separate experiments, error bars represents SD. (E): Whole mount immunofluorescence analysis of control spheroids (con) and
PDGFR inhibitor-IV spheroids (IV) cultured for 5 days, showing CDH1 (red) expression with DAPI-stained nuclei (blue). Scale bars5 50
mm. Abbreviations: AFP, a-fetoprotein; ESC, embryonic stem cell.
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PECAM-1 protein (1.636 0.13-fold and 1.686 0.15-fold,
respectively) (Supporting Information Fig. S4C); however, this
level was lower than that expressed by PDGFR inhibitor-IV or
FN-depleted spheroids.
MSC Spheroids Secrete Angiogenic Factors
To identify proteins secreted by MSC spheroids which may regu-
late the endothelial features identified, we used a human angio-
genesis proteome array to analyze supernatants from adherent
2D MSCs at high density, or 3D MSC spheroids, cultured in the
presence or absence of PDGFR inhibitor-IV for 3 days (Fig. 5).
Compared to adherent controls, both control and PDGFR-IV
spheroids prominently upregulated the secretion of activin-A,
ADAMTS-1, dipeptidyl peptidase-4, EGF, endostatin, FGF-1, glial
cell line-derived neurotrophic factor, IGFBP-1, IL-8, PlGF, and
VEGF-C, but downregulated the secretion of angiopoietin-1,
FGF-7, monocyte chemotactic protein-1, and thrombospondin-
1. Compared to control spheroids, PDGFR-IV spheroids secreted
higher levels of ADAMTS-1 (1.56 0.12-fold), endoglin
(1.56 0.13-fold), FGF-1 (1.66 0.11-fold), HGF (1.76 0.13-fold),
vasohibin (1.56 0.12-fold), and VEGF-C (1.36 0.09-fold), but
markedly decreased the secretion of amphiregulin (3.96 0.3-
fold), IL-8 (1.56 0.12-fold), and leptin (2.56 0.2-fold). A list of
Figure 4. PDGFR and FN-inhibited spheroids upregulate endothelial markers. (A): Quantitative RT-PCR analysis of PECAM-1 and VE-
cadherin expression within high-density adherent mesenchymal stromal/stem cells (MSCs) (Adh Con), high-density adherent MSCs
exposed to PDGFR inhibitor-IV (Adh IV), control spheroids (Sph Con), and PDGFR inhibitor-IV spheroids (Sph IV), cultured for 5 days.
Data are relative to GAPDH and normalized to adherent control levels. *, p< .001 compared with adherent controls, #, p< .001 com-
pared with control spheroids, using paired t test n 5 3 separate experiments, error bars represent SD. (B): Quantitative RT-PCR analysis
of PECAM-1 and VE-cadherin expression within control spheroids (Con) and PDGFR inhibitor-IV spheroids (IV), cultured for 1, 2, 3, and 5
days. Data are relative to GAPDH and normalized to the level of control spheroids at day 1. *, p< .001 compared with day 1 control
spheroids, using paired t test n 5 3 separate experiments, error bars represent SD. (C, D): Whole mount immunofluorescence analysis
of (C) control spheroids (con) and (D) PDGFR inhibitor-IV spheroids (IV), cultured for 5 days, showing PECAM-1 (red) and VE-cadherin
(green) expression, with DAPI-stained nuclei (blue). Scale bars5 50 mm. (E, F): Immunoblot analysis of PECAM-1 expression within con-
trol (Con), PDGFR inhibitor-IV (IV) spheroids, HUVECs (EC) and control scrambled siRNA spheroids (Scr #), and FN knockdown spheroids
(FN #) after 5 days culture, with b-actin as loading control. Histogram shows PECAM-1 expression relative to b-actin and normalized to
control spheroid or control siRNA spheroid levels. *, p< .001 compared with control spheroids, #, p< .001 compared with PDGFR
inhibitor-IV spheroids, using paired t test n 5 3 separate experiments, error bars represent SD. (G): Quantitative RT-PCR analysis of
PECAM-1 and VE-cadherin expression within control spheroids, cultured for 5 days in the presence of DMSO (DM) carrier, or 0.1 mM
PDGFR inhibitor-IV, 2 nM EGFR, 0.1 mM FGFR, 0.5 mM VEGFR, 5 nM ROK, 50 mM Rac1, 20 mM MEK, or 5 mM PI3K inhibitors. Data are
relative to GAPDH and normalized to DMSO treated spheroid levels. *, p< .001 compared with control spheroids, using paired t test n
5 3 separate experiments, error bars represent SD. Abbreviations: FN, fibronectin; PDGFR, platelet-derived growth factor receptor.
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the relative expression levels of all 55 secreted proteins is given
in Supporting Information Table S3.
Taken together, these data demonstrate that the 3D culture
of MSCs as spheroids markedly increased the secretion of potent
angiogenic-related proteins, and dramatically upregulated the
expression of PECAM-1 and VE-cadherin transcripts, compared
with 2D culture of MSCs at high density. Furthermore, PDGFR
inhibitor-IV and FN-depleted spheroids displayed an increase in
PECAM-1 protein when compared with control spheroids, indi-
cating that inhibition of mesenchymal drivers is a primary deter-
minant in the acquisition of these endothelial features.
MSC Spheroids Facilitate Blood Vessel Formation
Within Matrigel
Endothelial cells form capillary-like network structures when
cultured on Matrigel [36]. We therefore tested the ability of
MSCs which had been cultured as spheroids, to form similar
Matrigel-induced networks. Control and PDGFR inhibitor-IV
spheroids were cultured for 5 days, then MSCs dissociated
into single cells and cultured on Matrigel under identical con-
ditions (i.e., no PDGFR inhibitor-IV added) for a further 2
days. PECAM-1 and VE-cadherin expressions were then deter-
mined by immunofluorescence analysis (Fig. 6A, 6B). MSCs
derived from control spheroids readily established network
structures with elongated branch points. These networks were
composed of spindle-shaped cells which expressed both
PECAM-1 and VE-cadherin (Fig. 6A). However, some cells
expressed neither PECAM-1 nor VE-cadherin (Fig. 6A (ii, iv)).
Similarly MSCs derived from PDGFR inhibitor-IV spheroids also
readily formed widespread network structures, but in con-
trast, these had short branch points and the networks were
composed of rounded cells, surrounded by distinctive PECAM-
1 and VE-cadherin expression (Fig. 6B). Notably in this case,
from >25 different images captured, every cell was positive
for both PECAM-1 and VE-cadherin (Fig. 6B (ii-iv)).
As a prelude to examining the effects of MSC spheroids on
angiogenesis in vivo, we cultured MSC spheroids within a 3D
Matrigel plug in vitro. Control and PDGFR inhibitor-IV spheroids
were cultured for 5 days. The intact spheroids were then
implanted into Matrigel and cultured under identical conditions
(i.e., no PDGFR inhibitor IV added) for a further 5 days. Control
spheroids rapidly developed outgrowths of spindle-shaped cells
by day 1, which became extensive by day 5 (Fig. 6C). These cel-
lular outgrowths were negative for PECAM-1 and VE-cadherin
(Fig. 6D (i-ii)), but positive for SMA (Fig. 6D (iii)). In contrast,
PDGFR inhibitor-IV spheroids developed a ring of nonmigratory
rounded cells around the spheroid periphery (Fig. 6E), which
exhibited abundant PECAM-1 and VE-cadherin expression (Fig.
Figure 5. Angiogenic factors secreted by mesenchymal stromal/stem cell (MSC) spheroids. A human angiogenesis array kit (ARY007)
(R&D Systems, Minneapolis, MN, http://www.rndsystems.com) was used to determine simultaneously the relative expression levels of
55 different angiogenic proteins, secreted by high-density adherent MSCs (Adh Con), high-density adherent MSCs exposed to PDGFR
inhibitor-IV (Adh IV), control spheroids (Sph Con), and PDGFR inhibitor-IV spheroids (Sph IV), cultured for 3 days. Prior to analysis,
adherent MSCs and spheroids were cultured for 2 days, then fresh growth medium added and cultured for a further 3 days for analysis.
Supernatants from 24 identical adherent or spheroid cultures were pooled for analysis. Data are normalized to the DNA content of each
MSC culture, and relative to high-density adherent MSCs (Adh con) *, p< .001 compared with adherent controls, #, p< .005 compared
with control spheroids, using paired t test n5 1 experiment, error bars represent SD between two repeats.
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6F). Live cell imaging was also used to monitor the formation of
cellular outgrowths from control spheroids and the peripheral
ring of cells around PDGFR inhibitor-IV spheroids, during the
first 90 hours of culture within Matrigel (Supporting Informa-
tion Video S2).
PDGFR-Inhibited MSCs Integrate with Functional In
Vivo Blood Vessels
To determine the effects of MSC spheroids on in vivo angio-
genesis, 10 control or PDGFR inhibitor-IV spheroids were sus-
pended in Matrigel without any additional growth factors,
and implanted into mice for 14 days, then human and
murine PECAM-1 expression determined by immunofluores-
cence (Fig. 7). In addition, new functional blood vessels con-
nected to the circulation were identified by FITC-dextran
perfusion.
Examination of excised Matrigel plugs revealed that the
control spheroids contained few human PECAM-1 positive
cells present (Fig. 7A), but these spheroids were infiltrated
by murine PECAM-1 positive blood vessels; the absence of
FITC-dextran staining suggested that these vessels were not
attached to the circulation (Fig. 7B). Similarly, the Matrigel
surrounding the control spheroids was permeated with
murine PECAM-1 positive blood vessels; however, few
human PECAM-1-positive cells were observed (Fig. 7B), and
these vessels were also not associated with FITC-dextran
perfusion (Fig. 7D). Analysis of the peripheral tissue revealed
numerous blood vessels (Fig. 7C), but only minimal human
PECAM-1-positive staining was detected (Fig. 7D), which
again was not detected near FITC-dextran staining (Fig. 7F).
In marked contrast, PDGFR inhibitor-IV spheroids con-
tained numerous human PECAM-1-positive cells and these
spheroids were also infiltrated by murine blood vessels (Fig.
7G), which were connected to the host circulation as indi-
cated by abundant FITC-dextran perfusion (Fig. 7H). The
Matrigel surrounding PDGFR inhibitor-IV spheroids was also
permeated with both murine and human PECAM-1-positive
cells, which associated together in vascular-like assemblies
(Fig. 7I). Some of these human PECAM-1-positive vascular-like
assemblies within Matrigel were perfused with FITC-dextran
Figure 6. Spheroid-derived platelet-derived growth factor receptor (PDGFR)-inhibited mesenchymal stromal/stem cells (MSCs) form
Matrigel-induced networks. (A, B): Immunofluorescence analysis of MSCs cultured as spheroids for 5 days, then dissociated into single
cells (2 3 104) and cultured on glass coverslips (13-mm diameter) coated with a thin layer of growth factor reduced Matrigel for a fur-
ther 2 days. (A) MSCs derived from control spheroids (Con) and (B) MSCs derived from PDGFR inhibitor-IV spheroids (IV), showing net-
work formation and PECAM-1 (red) and VE-cadherin (green) expression, with DAPI-stained nuclei (blue). Image (iv) is shown split into
individual channels (v) green (VE-cadherin) and (vi) red (PECAM-1). Arrows in images A (ii, iv) represent MSCs lacking either PECAM-1 or
VE-cadherin. Scale bars5 200 mm (i) and 50 mm (ii-vi). (C, E): Bright-field images of (C) control spheroids (Con) and (E) PDGFR inhibitor-
IV spheroids (IV), implanted into Matrigel and cultured for 1 day and 5 days. Scale bars5 200 mm. (D, F): Whole mount immunofluores-
cence analysis of (D) control spheroids (Con) and (F) PDGFR inhibitor-IV spheroids (IV), implanted into Matrigel and cultured for 5 days,
showing PECAM-1 (red) and VE-cadherin (green) expression and (D (iii)) SMA (green) expression, with DAPI-stained nuclei (blue). Scale
bars5 200 mm (i) (D (iii)) and 50 mm (ii) (F (iii)).
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(Fig. 7J). Human PECAM-1-positive cells derived from PDGFR
inhibitor-IV spheroids were also detected in the peripheral tis-
sue, where they clearly integrated into blood vessels with
murine PECAM-1 positive cells (Fig. 7K). These human PECAM-
1-positive vessels in tissue were connected to the host vascu-
lature and perfused with FITC-dextran (Fig. 7L). Thus, PDGFR
inhibitor-IV spheroids are a potent source and stimulant for
neovascularization.
DISCUSSION
Mesenchymal cells make tissues by depositing and embedding
themselves in an extracellular matrix and growth factor-rich
microenvironment, which they remodel and maintain through-
out life. Although this extrinsic niche dictates the behavior of
MSCs, their therapeutic potential remains severely constrained
by lack of mechanistic insight into how the niche controls
their fate. Here, we have shown that disrupting the extracel-
lular matrix molecule FN or the functionally linked PDGFR,
which together regulate mesenchyme [22], converts MSCs
rapidly from SMA-rich spindle-shaped contractile cells to
rounded E-cadherin-rich cells. These cells exhibit enhanced
expression of markers for pluripotency, mesendoderm, endo-
derm, and angiogenic markers, and display potent angiogenic
behavior in vivo. Thus, blocking natural mesenchymal signals
offers an effective strategy for reprogramming mesenchymal
cells and for therapeutic revascularization.
We have developed a novel approach to modulate MSC
fate that does not require the use of viral vectors or exoge-
nous DNA. Using a spheroid MSC culture model that recapit-
ulates physiological features of a 3D cellular environment
and cell-cell interactions, MSCs were induced toward a more
multipotent state. Untreated MSCs within spheroids retained
their spindle-shape and mesenchymal character with a SMA-
rich cytoskeleton and profuse FN matrix. Although culturing
MSCs as 3D spheroids was sufficient to induce some upregu-
lation of mesendodermal and endodermal markers, inhibi-
tion of PDGFRs or FN knockdown induced rapid cell
rounding along with significant further induction of pluripo-
tency markers Oct4A and Nanog, demonstrating that MSCs
have the potential to revert to a premesenchymal state,
which is accentuated when mesenchymal signals are inhib-
ited. We have previously shown using 2D cultured MSCs that
PDGFR signaling inhibition changes their shape and cell fate
[28]. In this study, depletion of the extracellular matrix
Figure 7. Spheroid-derived platelet-derived growth factor receptor (PDGFR)-inhibited mesenchymal stromal/stem cells integrate with
perfused blood vessels. (A–L): Immunofluorescence analysis of Matrigel plugs containing control or PDGFR inhibitor-IV spheroids, after
implantation in mice for 14 days, showing human (Hu) PECAM-1 (red) and murine (Ms) PECAM-1 (green) expression, or FITC-dextran
(FITC-dx) perfusion (green), with DAPI-stained nuclei (blue). Images show representative areas of (A, B) control or (G, H) PDGFR
inhibitor-IV spheroids. Matrigel surrounding (C, D) control or (I, J) PDGFR inhibitor-IV spheroids. Tissue surrounding (E, F) control or (K,
L) PDGFR inhibitor-IV spheroids. Images K and L are shown split into their red channel (human PECAM-1) and green channel (murine
PECAM-1 or FITC-dextran perfusion). Scale bars5 50 mm.
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component FN was also shown to modulate MSC shape and
direct their fate, emphasizing the crucial role played by cell
shape in MSC fate decisions. Furthermore, we were able to
demonstrate that these cells had strong angiogenic potential
in vitro and in vivo. Thus, disrupting mesenchymal signals in
these 3D cultures induced a mesenchymoangioblast-like state
[3, 4].
It has been unclear whether MSCs possess the ability to
transdifferentiate to functional endothelial cells; most reports
have relied on exogenous VEGF-A supplementation
approaches [8]. We previously showed that high-density cul-
tures exhibited Notch-dependent endothelial potential in vitro
and in CAM assays [9]. Here, by demonstrating that MSCs
derived from PDGFR-inhibited spheroids are able to induce,
and integrate with functional blood vessels perfused by the
circulation in vivo, we have directly shown their angiogenic
and vascular potential. By inhibiting mesenchymal signals, we
were able to induce endothelial fate, including the reinstiga-
tion of robust cell-cell interactions, as judged by E-cadherin
expression. Thus cell-cell contacts within PDGFR-inhibited
spheroids may be just as important in driving the angiogenic
features, as increased expression of embryonic transcription
factors.
CONCLUSION
In summary, we have shown that the mesenchymal fate of
MSCs can be modulated by re-engineering the relationship
between cells and their local matrix, without the need
for viral delivery of exogenous transcription factors. By block-
ing mesenchymal drivers, these cells can be reverted to a
mesenchymoangioblast-like state and thence to functional
endothelial-like cells in vivo. As these strategies target the
natural mechanisms that manipulate mesenchymal fate, they
have great potential for future revascularization therapies.
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